Back to search

Germany· DE-A57-676bdc70ec08790b

Imipenem/Cilastatin Steriscience

A medicinal product containing cilastatin, imipenem, registered in Germany by Steriscience B.V..

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedImipenem/Cilastatin SteriscienceATC—REGISTER NO.DE-A57-676bdc70ec0879…PACKS LISTED0CHECKEDSeptember 30, 2026

The record

At a glance

EMA Article 57 (European Union)
Active substance
Cilastatin, Imipenem
Manufacturer
Steriscience B.V.
Country
Germany (DE)
ATC code
—
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Cilastatin, imipenem in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cilastatin, imipenem products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Imipenem/Cilastatin Aptapharma, Imipenem/Cilastatin Eberth
  • Bulgaria · Имипенем/Циластатин Аптафарма, Мирон
  • Cyprus · Imicilast, Imipenem + Cilastatina Venus Pharma
  • Czechia · Enaros, Imipenem/Cilastatin Aptapharma
  • Denmark · Andatin, Imipenem/Cilastatin Noridem
  • Estonia · Imipenem/Cilastatin Kabi
  • Spain · Enaros, Imipenem/Cilastatina Aurovitas
  • Finland · Andatin, Imipenem/Cilastatin Noridem
  • France · Imipenem Cilastatine Panpharma, Imipenem Cilastatine Sun
  • United Kingdom (Northern Ireland) · Imipenem/Cilastatin Accord Healthcare, Imipenem/Cilastatin Fresenius Kabi
  • Greece · Imicil, Imipenem+cilastatin /Kabi
  • Croatia · Imipenem/Cilastatin Aptapharma, Imipenem/Cilastatin Kabi
  • Hungary · Imipenem/Cilastatin Aptapharma, Imipenem/Cilastatin Kabi
  • Ireland · Imipenem/Cilastatin, Imipenem/Cilastatin Hikma Farmacêutica Portugal
  • Italy · Imipenem E Cilastatina Aurobindo, Imipenem E Cilastatina Hikma Farmacêutica
  • Lithuania · Imipenem/Cilastatin Sun, Stinem
  • Latvia · Imipenem/Cilastatin Sun
  • Malta · Imipenem/Cilastatin Aptapharma, Miron
  • Netherlands · Imipenem/Cilastatine Fresenius Kabi, Imipenem/Cilastatine Hikma
  • Norway · Andatin, Imipenem/Cilastatin Fresenius Kabi
  • Poland · Imipenem + Cilastatin Aptapharma, Imipenem + Cilastatin Noridem
  • Portugal · Enaros, Imipenem + Cilastatina Aurovitas
  • Romania · Cilopen, Imipenem/Cilastatin Aptapharma
  • Sweden · Imipenem/Cilastatin Fresenius Kabi, Imipenem/Cilastatin Noridem
  • Slovenia · Imipenem/Cilastatin Aptapharma, Imipenem/Cilastatin Kabi
  • Slovakia · Imipenem/Cilastatin Aptapharma, Imipenem/Cilastatin Kabi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db7c4939-c8e2-4803-8363-7c29556d12c8
GET /v1/drugs/db7c4939-c8e2-4803-8363-7c29556d12c8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Cilastatin, Imipenem",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about cilastatin, imipenem.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.